aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Company profile
Ticker
SYRE
Exchange
Website
CEO
Anthony G. Quinn
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aeglea BioTherapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Spyre Therapeutics LLC • Aeglea Development Company, Inc. • AERase, Inc. • AECase, Inc. • AEMase, Inc. • AE4ase, Inc. • AE5ase, Inc. • AE6ase, Inc. • Aeglea Biotherapeutics UK Limited • Aeglea Ireland Limited ...
SYRE stock data
Latest filings (excl ownership)
S-1
IPO registration
18 Apr 24
ARS
2023 FY
Annual report to shareholders
2 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
POS AM
Prospectus update (post-effective amendment)
26 Mar 24
PRE 14A
Preliminary proxy
20 Mar 24
424B3
Prospectus supplement
18 Mar 24
8-K
Spyre Therapeutics Announces $180 Million Private Placement
18 Mar 24
POS AM
Prospectus update (post-effective amendment)
14 Mar 24
Transcripts
Latest ownership filings
SC 13G/A
FMR LLC
11 Mar 24
4
Cameron Turtle
20 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G/A
Logos Global Management LP
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 91.90 mm | 91.90 mm | 91.90 mm | 91.90 mm | 91.90 mm | 91.90 mm |
Cash burn (monthly) | 48.26 mm | (no burn) | 13.37 mm | 24.60 mm | 11.53 mm | 7.25 mm |
Cash used (since last report) | 328.27 mm | n/a | 90.93 mm | 167.31 mm | 78.45 mm | 49.33 mm |
Cash remaining | -236.38 mm | n/a | 964.56 k | -75.41 mm | 13.45 mm | 42.57 mm |
Runway (months of cash) | -4.9 | n/a | 0.1 | -3.1 | 1.2 | 5.9 |
Institutional ownership, Q3 2023
78.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 33 |
Opened positions | 3 |
Closed positions | 21 |
Increased positions | 0 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 39.51 bn |
Total shares | 28.81 mm |
Total puts | 4.00 |
Total calls | 56.00 |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners III | 7.98 mm | $3.04 mm |
BCLS II Equity Opportunities | 5.35 mm | $0.00 |
EcoR1 Capital Fund Qualified | 5.00 mm | $2.28 mm |
Integrated Core Strategies | 3.13 mm | $0.00 |
Lilly Ventures Fund I | 2.57 mm | $20.21 mm |
LLY Lilly(Eli) & Co | 1.53 mm | $7.25 mm |
Driehaus Capital Management | 800.85 k | $9.81 bn |
Fairmount Funds Management | 378.42 k | $4.64 bn |
Polar Capital | 300.00 k | $3.68 bn |
Wellington Management | 299.93 k | $3.67 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Feb 24 | Turtle Cameron | Common Stock | Grant | Acquire A | No | No | 9.82 | 400 | 3.93 k | 746,907 |
1 Feb 24 | Heidy King-Jones | Stock Option Common Stock | Grant | Acquire A | No | No | 25.86 | 63,000 | 1.63 mm | 63,000 |
1 Feb 24 | Scott L Burrows | Stock Option Common Stock | Grant | Acquire A | No | No | 25.86 | 70,000 | 1.81 mm | 70,000 |
1 Feb 24 | Turtle Cameron | Stock Option Common Stock | Grant | Acquire A | No | No | 25.86 | 277,750 | 7.18 mm | 277,750 |
News
Stifel Reiterates Buy on Spyre Therapeutics, Raises Price Target to $54
26 Mar 24
Stifel Maintains Buy on Spyre Therapeutics, Raises Price Target to $54
26 Mar 24
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
5 Mar 24
Wells Fargo Upgrades Spyre Therapeutics to Overweight, Raises Price Target to $35
1 Mar 24
Spyre Therapeutics Q4 EPS $(4.05) Up From $(5.00) YoY
29 Feb 24
Press releases
Spyre Therapeutics Announces Grants of Inducement Awards
1 Apr 24
Spyre Therapeutics Announces Grants of Inducement Awards
1 Mar 24
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
8 Feb 24
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
5 Feb 24
Spyre Therapeutics Announces Grants of Inducement Awards
2 Feb 24